Vision
Our vision is to lead a global transformation in women’s cancer prevention and early diagnosis by making innovative, accessible, and personalized solutions the Standard Of Care—empowering women worldwide to live healthier lives.
Mission
Our mission is to address unmet needs in women’s cancer prevention and diagnosis by delivering personalized care through innovative epigenetic solutions, driving global access to improve outcomes for women across the globe.
Value Proposition
At Sola Dx, we are revolutionising personalised primary and secondary prevention through ground-breaking innovations, including the WID®-easy Test for the early detection of endometrial cancer and the WID®-can Test for cervical cancer risk prediction.
Our key focus is driving the rapid adoption of the WID®-easy Test among symptomatic women in major global markets, laying the groundwork for population-wide screening and unlocking substantial market potential.
The WID®-can Test is poised to redefine cervical cancer screening as a non-cytology molecular triage tool. Unlike traditional methods reliant on cellular morphology, the WID®-can Test can be performed on self-collected samples, offering superior objectivity, reproducibility, and accessibility compared to current standards.
The WID®-ok Test is designed to identify women at high risk for ovarian cancer, regardless of genetic predisposition. By detecting risk factors beyond hereditary mutations, the WID®-ok Test enables proactive prevention, offering a crucial opportunity to intervene before this highly lethal disease develops.
The WID®-best Test represents a breakthrough in breast cancer risk stratification by leveraging an epigenetic signature detected in cervical smear samples. This cutting-edge test identifies women at heightened risk of developing breast cancer, enabling personalized primary prevention strategies and facilitating risk-adjusted screening protocols.
Through our unwavering commitment to innovation, we are addressing the critical diagnostic needs of women today while paving the way for a future where personalized, accessible, and effective cancer prevention becomes the global Standard Of Care.
What We Do
We develop and market minimally invasive epigenetic diagnostic tools, including the WID®-easy and WID®-can Tests, designed to detect gynaecological cancers at an early stage, when treatments are most effective, and success rates are highest. Leveraging the same cervico-vaginal sample, we are pioneering the development of adaptable epigenetic risk markers, such as the WID®-best Test, with the potential to enable personalized prevention strategies for other women’s cancers as well.
Why We're Different
At Sola Dx, we are a commercial-stage epigenetic diagnostics company built on over 30 years of ground-breaking research in DNA methylation and gynaecological cancers. Our technologies originate from the pioneering work of Prof. Martin Widschwendter and his world-renowned academic team. Leveraging cutting-edge epigenetic science, we develop diagnostic tests that are both highly accurate and minimally invasive. By focusing on tailored precision prevention, we empower women with the knowledge and tools to make better informed health decisions, setting us apart as leaders in women’s health diagnostics.
Leadership Team
Advisory Council (Beirat)
Hon. Prof. Adeola Olaitan
Advisor for Gynaecological Oncology
Prof. Nora Pashayan
Advisor for Risk-Stratified Cancer Screening
Prof. Silvia de Sanjosé
Advisor for Viral Oncology and Epidemiology
Prof. Martin Widschwendter
Executive Chair, Founder
Angus MacLennan
Non-Executive Chair
Mag. Manfred Pletzer
Member of the Board, Investor
Executive Team
Prof. Martin Widschwendter
Chief Executive Officer
More
Prof. Martin Widschwendter is the founder and Chief Executive Officer of Sola Diagnostics.
A globally recognized expert in women’s health diagnostics with over 30 years of pioneering research in DNA methylation and gynecological cancers, he combines scientific excellence with strategic leadership. As CEO, Prof. Widschwendter drives the company’s mission to transform cancer prevention and early detection through epigenetics. His groundbreaking work underpins Sola Diagnostics’ core technologies, including the WID®-easy, WID®-can, and WID®-best Tests. With a unique ability to translate academic innovation into impactful clinical solutions, he ensures that Sola Diagnostics remains at the forefront of precision diagnostics and women’s health.
Peter Ince
Chief Operating Officer
More
Peter Ince is the Chief Operating Officer of Sola Diagnostics.
With decades of experience in operational leadership and organizational scaling, he oversees the company’s day-to-day operations and ensures efficiency across all functions. As COO, Peter plays a critical role in translating strategy into execution—supporting the commercial rollout of Sola’s diagnostic solutions while optimizing internal processes for growth. His deep expertise in operational excellence and cross-functional alignment enables Sola Diagnostics to deliver on its mission of advancing women’s health through high-quality, globally scalable diagnostic technologies.
Dr. Peter Kayatz
Chief Commercial Officer
More
Dr. Peter Kayatz is the Chief Commercial Officer of Sola Diagnostics.
With over 20 years of experience in life sciences management and business strategy, he leads the company’s global commercial activities, including business development, strategic partnerships, and market expansion. Dr. Kayatz is dedicated to bringing innovative diagnostic solutions to market that address critical unmet needs in women’s health. Drawing on a strong track record in leadership roles across biotech and diagnostic companies, he combines strategic insight with operational execution to drive the commercial success of Sola Diagnostics and support its long-term growth.
Sara Sleigh, PhD
Chief Development Officer
More
Dr. Sara Sleigh oversees clinical development at Sola Diagnostics, managing the design, execution, and regulatory approval of clinical trials for the company’s diagnostic products. With extensive experience in clinical research and development, she ensures that Sola’s solutions meet regulatory requirements and demonstrate clinical efficacy. Dr. Sleigh’s leadership drives the transition of diagnostic innovations, like the WID®-easy and WID®-best Tests, from research to real-world application. Her commitment to advancing women’s health through evidence-based diagnostics positions Sola Diagnostics as a trusted partner in the field of gynecological and breast cancer prevention.
Elisa Redl, PhD
Head of Analytical Development
More
Dr. Elisa Redl is the Head of Analytical Development at Sola Diagnostics, where she ensures the scientific rigor and technical accuracy of the company’s diagnostic assays. With a PhD in molecular diagnostics, she specializes in assay development, validation, and optimization for innovative diagnostic tools. Dr. Redl plays a critical role in advancing the technical capabilities of the WID®-easy, WID®-can, and WID®-best Tests. Her expertise ensures that Sola Diagnostics’ products meet the highest standards of analytical performance, enabling precise and reliable results. Dr. Redl is passionate about translating science into impactful solutions for women’s health.
Dr. Chiara Herzog
Head of Epigenetic Biomarker Innovation
More
Dr. Chiara Herzog is Head of Epigenetic Biomarker Innovation at Sola Diagnostics, where she contributes to the scientific direction of DNA methylation-based diagnostics. An expert in translational epigenetics with a background in molecular medicine, she has authored seminal papers and contributed to key intellectual property underpinning Sola’s biomarker portfolio, including the WID®-easy and WID®-can Tests. Dr. Herzog also plays an active role in international consortia advancing biomarker standards, helping bridge academic discovery and clinical implementation in women’s health and ageing research.
James Barrett, PhD
Head of Statistics & Bioinformatics
More
Dr. James Barrett leads statistical and bioinformatics strategies at Sola Diagnostics, ensuring the robustness and reliability of the company’s data-driven insights. With a PhD in bioinformatics and extensive experience in statistical modeling, he plays a pivotal role in developing algorithms and methodologies that underpin the performance of the WID®-easy, WID®-can, and WID®-best Tests. Dr. Barrett’s expertise ensures that the company’s diagnostic solutions are validated through rigorous analysis, delivering reliable and actionable results for patients and clinicians. His work enables Sola Diagnostics to maintain its position at the forefront of precision medicine.
Mag. David Tschabitscher
Head of Communications
More
Mag. David Tschabitscher is the Head of Communications at Sola Diagnostics, where he develops and executes communication strategies that effectively convey the company’s vision and mission. With a strong background in public relations and corporate communication, he ensures that Sola Diagnostics’ messaging resonates with stakeholders, including investors, partners, and the broader healthcare community. David is instrumental in shaping the company’s brand identity and promoting its innovative diagnostic solutions globally. His efforts enhance Sola’s visibility and reputation as a leader in women’s health diagnostics, fostering trust and engagement with key audiences.
Our Impact
Our innovative diagnostics are designed to reduce morbidity and mortality from women’s cancers through precision prevention and early detection.
The WID®-easy Test minimises the need for unnecessary surgical procedures, lowering healthcare costs, protecting women from invasive interventions, and enhancing the effectiveness of early cancer detection.
The WID®-can Test benefits patients by offering an accessible, minimally invasive cervical cancer screening solution that can be performed on self-collected samples, reducing discomfort, increasing accessibility, and delivering more accurate and reproducible results.
The WID®-best Test empowers women by identifying their elevated risk of breast cancer through minimally invasive analysis of cervical smear samples, enabling personalized prevention strategies and proactive health management.
Our Values
- Patient-Focussed: We prioritize the well-being and needs of women, ensuring our diagnostic solutions are accessible, minimally invasive, and designed to improve patient outcomes.
- Scientific Excellence: Our work is grounded in over 30 years of pioneering research in DNA methylation and women’s cancers, led by Prof. Martin Widschwendter.
- Innovation: We leverage cutting-edge epigenetic research to develop advanced precision prevention tests that are both highly accurate and minimally invasive.
- Integrity: We uphold the highest ethical standards in our research, partnerships, and operations.
- Collaboration: We work with global partners to expand access and improve outcomes in women’s health diagnostics.
- Empowerment: We provide women with the knowledge and tools to take charge of their health and well-being.
Milestones
2020
- Sola Diagnostics GmbH was established by Prof. Martin Widschwendter in Tyrol, Austria, leveraging decades of expertise in epigenetic research.
2021
- Licensing agreement with the University College London
- Convertible Loan by the University of Innsbruck
2022
-
Equity Financing by a consortium of four Tyrolean business angels
-
The development and initial validation of WID®-easy, WID®-can, and WID®-best have been published in leading scientific journals, including the Journal of Clinical Oncology, Clinical Epigenetics, and Nature Communications.
2023
- WID®-easy Test’s performance published in The Lancet Oncology
2024
-
WID®-easy Test launched in Austria and Switzerland
-
WID®-can Test’s performance published in Nature Medicine
-
WID®-easy Test UKCA-marked
2025
- WID®-easy Test launched in the UK